2don MSN
AstraZeneca PLC (NASDAQ:AZN) Announces Strategic Collaboration Agreement With CSPC Pharmaceuticals
AstraZeneca PLC (NASDAQ:AZN) is one of the best long term low volatility stocks to invest in. AstraZeneca PLC (NASDAQ:AZN) announced on January 30 that it is bolstering its weight management portfolio ...
AstraZeneca deepens its obesity push with an eight-program deal with China's CSPC, securing rights to a once-monthly ...
AstraZeneca is handing $1.2 billion in upfront cash to CSPC Pharmaceuticals for the ex-China rights to the biopharma’s ...
6don MSN
AstraZeneca strikes deal for up to $18.5 billion to license weight-loss drugs from China's CSPC
By Andrew Silver SHANGHAI, Jan 30 (Reuters) - AstraZeneca will license experimental drugs for obesity and weight-related ...
The deal, which involves up to eight “next-generation” weight loss medications and could be worth more than $18 billion, ...
AstraZeneca entered a strategic collaboration with CSPC Pharmaceuticals to expand its weight management and metabolic disease ...
AstraZeneca's full-year 2025 results are due on 10 February. Learn what investors should watch including Tagrisso sales, ...
AstraZeneca enhances its weight management portfolio through collaboration agreement with CSPC Pharmaceuticals: Cambridge, UK Saturday, January 31, 2026, 09:00 Hrs [IST] AstraZene ...
AstraZeneca has fronted $100 million to head deeper into the KRAS space, securing the rights to a clinical-stage, multitarget asset from China’s Jacobio Pharma. U.K.-based AstraZeneca has scored the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results